In the wound environment there are many factors that will influence the speed of healing, or even whether the wound will heal at all. These include biofilm, infection, chronic inflammation and moisture imbalance. At any one time one or more of these factors may need addressing. The Io-Cyte concept works on the local environment with a four-in-one action (see figure) to address as many of these factors as possible. Our research shows that with the Io-Cyte technology we can target the combination of antimicrobial and biofilm disrupting action with an anti-inflammatory effect while also absorbing excess wound fluid. Io-Cyte’s antibacterial properties are achieved without use of silver.
This fits in the Wound Bed Preparation concept (1) that is the basis of most modern wound healing and linked to the commonly used TIME acronym (Tissue, Infection/Inflammation, Moisture balance and Edge of wound) (2) or variants that lists the areas to address in managing the wound bed for healing.
Research on the antimicrobial properties and biofilm-disruption of Io-Cyte have been published at Wounds UK 2019 (3), showing that the product is capable of disrupting established gram-positive and gram-negative biofilms as well as being bactericidal to planktonic bacteria in laboratory models. Please contact us for a copy of the poster.
Antimicrobial performance was tested using the AATCC test method 100, the industrial standard in the USA for antimicrobial fabric performance. In this study, treatment with test samples of Io-Cyte resulted in at least a 4 Log reduction in the recovery of S. aureus and P. aeruginosa. This result indicates that the dressing is bactericidal.
We also tested the dressing’s ability to eradicate bacterial biofilms. Biofilms are matrix-enclosed communities of bacteria that are significantly less susceptible to host defences and to conventional therapies, compared to the same bacteria in isolation. Eradication of biofilm infections may result in improved patient outcomes and a decrease in healthcare costs. In the CDC reactor test used is a UKAS accredited method for measuring effectiveness against established biofilms. Treatment of biofilm with Io-Cyte test dressings resulted in a greater than 4 Log reduction in S. aureus and P. aeruginosa (see graphs).
Demonstration of biofilm eradication in vitro provides a strong basis for future work to show the potential for effective treatment in-vivo and clinically. Eradication of biofilm infections on wounds may result in improved patient outcomes and a decrease in healthcare costs.
(1). Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen, 2000; 8(5): 347-52.
(2). Schultz, G. S., Sibbald, R. G., Falanga, V., Ayello, E. A., Dowsett, C., Harding, K., Romanelli, M., Stacey, M. C., Teot, L. and Vanscheidt, W. (2003), Wound bed preparation: a systematic approach to wound management. Wound Repair Regen, 11: S1–S28. doi:10.1046/j.1524-475X.11.s2.1.x
(3). Agboh, C., Farrar, D.F., Pine, J., Durkin, G., Fabbri, S., Thomas, H. and Westgate, S.J. (2019), The anti-bacterial and biofilm disruption activity of absorbent sustained-action alginate and iodine-combined wound dressings. Poster presented at Wounds UK, Harrogate, November. Copy of poster available on request .